Form 4: Arcellx Director Andrew Galligan Reports Ownership Changes

Andrew H. Galligan, a Director at Arcellx, Inc., reported transactions related to his beneficial ownership of common stock and stock options following the company's merger with Gilead Sciences.

Summary

• Andrew H. Galligan, a Director at Arcellx, Inc., has reported changes in his beneficial ownership of company securities.
• These changes stem from the merger agreement between Arcellx, Inc. and Gilead Sciences, Inc., which was completed on April 28, 2026.
• Galligan's common stock holdings were exchanged as part of the tender offer and subsequent merger.
• His stock options were canceled and converted into a right to receive a cash payment and a contingent value right (CVR).
• The cash payment for each option is calculated as the difference between the closing amount ($115.00 per share) and the option's exercise price, multiplied by the number of shares subject to the option.
• Additionally, each canceled option entitles the holder to one CVR, representing a contingent payment of $5.00 per CVR.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing, as it confirms the completion of a merger with a substantial cash payout and contingent value rights for shareholders and option holders, indicating a successful exit event.

Positives

• The merger with Gilead Sciences provides a significant financial event for Arcellx shareholders and option holders.
• Stock options were converted into cash payments and contingent value rights, providing immediate and potential future value.
• The closing amount of $115.00 per share in cash for common stock represents a substantial premium for tendering shareholders.

Negatives

• Outstanding stock options were canceled rather than being directly converted into new equity, though they were compensated.
• The value of the CVR is contingent on future events and payments, introducing an element of uncertainty.

Risks

• The value of the contingent value right (CVR) is subject to the terms and conditions of the CVR agreement and may not be realized.
• Withholding taxes may apply to cash payments received from the cancellation of stock options and the closing amount.

Future Outlook

The filing primarily details past transactions related to a completed merger. Future outlook is implicitly tied to the success of the contingent value rights and the integration of Arcellx into Gilead Sciences.

Management Comments

• The filing details the conversion of stock options into cash payments and contingent value rights as per the merger agreement.
• It also specifies the exchange of common stock for cash and contingent value rights.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects the completion of a significant acquisition in the biotechnology sector, where mergers and acquisitions are common strategies for larger pharmaceutical companies to access innovative drug candidates and technologies.

Comparison to Industry Standards

• The acquisition price of $115.00 per share, combined with a $5.00 CVR, represents a substantial premium, often seen in strategic acquisitions of promising biotech firms.
• The structure of the deal, including a cash component and a contingent value right, is a common mechanism used in the pharmaceutical and biotech industry to bridge valuation gaps between buyers and sellers, especially for companies with pipeline assets whose future value is uncertain.

Stakeholder Impact

• Shareholders: Received $115.00 per share in cash and one CVR for each share tendered.
• Option Holders: Had stock options canceled and converted into a cash payment (Closing Amount minus exercise price) and one CVR per option share.
• Employees: May be impacted by the change in ownership and integration into Gilead Sciences, with potential changes in roles and benefits.

Next Steps

• Shareholders and former option holders will receive cash payments and contingent value rights as per the merger agreement.
• The contingent value rights will be subject to future milestones and payments as outlined in the CVR agreement.

Key Dates

Keywords

Arcellx, ACLX, Form 4, SEC Filing, Insider Trading, Stock Options, Merger, Gilead Sciences, Beneficial Ownership, Andrew Galligan, Contingent Value Right